PDCD1 and cancer: In the past 10 years, there has been a huge development in cancer immunotherapies with the introduction of immune checkpoint inhibitor therapies towards programmed cell death protein 1 (PD-1), programmed death ligand-1 (PD-L1), and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) [1].